Cardiovascular diseases (CVD) including congenital heart disease have been the #1 cause of death, representing 1/3 of all deaths in the world, and more people die from CVDs than from any other diseases, according to the recent WHO report. Human induced pluripotent stem cells (iPSCs) have revolutionized current cardiovascular medicine and provided patient-derived and clinically relevant cardiac cells for disease modeling, cell transplantation therapy, and preclinical drug testing. Patient iPSCs can give rise to cardiomyocytes, endothelial cells, cardiac fibroblasts, and smooth muscle cells in the heart; thus providing enormous cell resources for studying complex genetics and gene-environment interactions simultaneously in multiple cell types. Coupled with state-of-the-art CRISPR/Cas9 genome editing and next-generation genome sequencing technologies, human iPSCs have been emerging as forerunners to transform our current understanding of cardiovascular development and diseases, and to integrate future precision medicine. In this Method Collection, we will present the current protocols to precisely and efficiently generate cardiomyocytes, endothelial cells, fibroblasts, and smooth muscle cells in the heart from human iPSCs using chemically defined approaches. The goal of this collection is to provide standardized protocols for robust generation and characterization of cardiomyocytes, endothelial cells, cardiac fibroblasts, and smooth muscle cells from human iPSCs in order to advance the iPSC technology in cardiovascular precision medicine. Finally, we highlight a 3D cardiac organoid differentiation method to generate beating mini-heart in the dish, which would represent the next phase of iPSC differentiation technology for cardiovascular medicine.